Facebook
Twitter
LinkedIn
ForwardNew Opportunities to Identify, Prevent, and Manage Fibrosis in Children’s Interstitial and Diffuse Lung Disease
Did you know that only 20% of surveyed physicians identified themselves as confident in most areas of diagnosing, understanding evidence based treatment options and disease mechanisms for pulmonary fibrosis in our pediatric patients? The Childhood ILD (chILD) Network has identified these needs in the medical community and aim to significantly improve these statistics.
This conference will be a two-day, interdisciplinary, hybrid course held live at the Gaylord of the Rockies in Aurora, Colorado. The conference will be free of charge to course attendees and CME credits will be available provided by Children’s Hospital Colorado.
chILD is a term used to describe over 200 rare conditions of children with diffuse and interstitial lung disease that can be associated with significant morbidity and mortality. Please join us to participate in a series of conversations on the outcomes of these studies and what the data means for the future of these rare conditions in our pediatric patient populations.
National thought leaders will present their findings on this new, innovative series of treatments for pediatric fibrosis. Led by the chILD Network which is comprised of 35 centers with multidisciplinary teams - new data has been published which will change the future of chILD. In addition, a subset of centers in the chILD Research Network participate in a prospective registry with over 23 children’s hospitals participating to enroll children into a database for longitudinal study. Pulmonary fibrosis is responsible for a large portion of cases, with up to 1/4 of all children having fibrosis as part of their lung disease process.
Hotel, Travel and other information on logistics can be found on this website.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals.
Target Audience
This activity is designed for Pediatricians, Internal Medicine-Pediatrics Physicians, Pediatric and Adult Pulmonologists, Rheumatologists, Oncologists, Immunologists, Pediatric Intensivists, Neonatologists, Radiologists, Pathologists, Advanced Practice Providers, Basic and Translational Scientists, and Clinical Research Coordinators.
Learning Objectives
1. Explain the conditions associated with childhood interstitial and diffuse lung disease (chILD).
2. Review the conditions associated with pulmonary fibrosis in older children.
3. List the diagnostic criteria and ongoing longitudinal follow up measurements in older children with pulmonary fibrosis.
4. Describe the pathogenesis of pulmonary fibrosis in older children with chILD.
5. Identify the interaction needed amongst different health care professionals (pediatricians, different specialists,) with the family and patient.
Additional Information
*All Times Listed Below are Mountain Time (Mountain Standard Time (MST), UTC -7).
The sessions will take place in Cottonwood 2-3
| Time | Title | Speaker |
| 7:15-8:15am | Breakfast & Arrivals | |
| Welcome | Robin Deterding, MD Matthew Stern, MS Children's Hospital Colorado | |
| A Patient's Journey | ||
| Basic information for Pediatric Pulmonary Fibrosis | ||
| 8:45 | What do pulmonologist know about pediatric pulmonary fibrosis? | Elizabeth Fiorino, MD Northwell Health |
| 9:05 | US chILD Registry experience and fibrosis | Rebekah Nevel, MD University of Missouri School of Medicine |
| 9:25 | Diagnostic Imaging for pediatric pulmonary fibrosis | Jason Weinman, MD Children's Hospital Colorado |
| 9:45 | Diagnostic Lung biopsy for Pediatric pulmonary fibrosis | Gail Deutsch, MD Seattle Children's Hospital |
| 10:05 | Question/Answer from Lecture Sessions #1 | Robin Deterding, MD Children's Hospital Colorado |
| 10:25am BREAK | ||
| 10:45 | Genetic approaches to Diagnosis Pediatric Pulmonary Fibrosis | Jen Wambach, MS, MD Washington University Physicians |
| 11:05 | Pathobiology of pulmonary fibrosis and disease treatment targets | James Hagood, MD University of North Carolina School of Medicine |
| 11:25 | Biomarkers and Outcome measures for Pediatric Pulmonary Fibrosis | Robin Deterding, MD Children's Hospital Colorado |
| 11:45 | Question/Answer from Lecture Sessions #2 | Timothy Vece, MD University of North Carolina, Children's Research Institute |
| 12:05pm LUNCH | ||
| Specific categories of Pulmonary Fibrosis | ||
| 1:00 PM | Pediatric Parenchymal Pulmonary and connective tissues disease | Grant Schulert, MD, PhD Cincinnati Children's Hospital |
| 1:50 | Pediatric Parenchymal Pulmonary Fibrosis and transplant | Samuel Goldfarb MD University of Minnesota Physicians |
| 2:40-3:00pm BREAK | ||
| 3:00 | Pediatric Parenchymal Pulmonary Fibrosis and Immune Dysregulation | Craig Platt, MD Boston Children's Hospital |
| 3:50 | Multidisciplinary care for pediatric pulmonary fibrosis | Alicia Casey, MD Boston Children's Hospital |
| 4:10 | Caring for Adolescents and Young Adults with Pulmonary Fibrosis | John Kennedy, MD Boston Children's Hospital |
| 4:25 | Panel discussion optimizing care and treatment approaches across silos. | |
| 4:45 pm Evaluation & Adjourn | ||
| Start of Day 2 | ||
| 7:15-8:15am Breakfast | ||
| 8:15am | Welcome | Robin Deterding, MD Children's Hospital Colorado |
| 8:30 AM | A Patient's Journey | |
| Growth, Development and Pediatric Pulmonary Fibrosis | ||
| 8:45am | Pulmonary vascular | Steve Abman, MD Children's Hospital Colorado |
| 9:05 | Pulmonary airway and Parenchyma | Jeff Whitsett, MD Cincinnati Children's Hospital |
| 9:25 | Chest wall and Pulmonary fibrosis | Greg Redding, MD Seattle Children's Hospital |
| 9:45 | Questions and discussion from Session #3 | Lisa Young, MD CHOP Research Institute |
| 10:05am BREAK | ||
| Novel research developments in Pediatric Pulmonary Fibrosis | ||
| 10:20 | Animal models | Lisa Young, MD CHOP Research Institute |
| 10:50 | Gene to functional therapy | John Kennedy, MD, MSc Boston Children's Hospital |
| 11:15 | iPSC and gene editing | Kostas Alysandratos, MD Boston University Medical Campus |
| 11:40 | Questions and discussion from Session #4 | Jen Wambach, MS, MD Washington University Physicians |
| Next steps for Pediatric Pulmonary Fibrosis | ||
| 12:00 | Closing the Gaps for the future | Robin Deterding, MD Children's Hospital Colorado |
| 12:20-12:30 | Adjourn and Evaluation | |
Travel
Discounted Hotel Rooms are available on a first come, first serve basis. Please contact Matthew Stern at matthew.stern@childrenscolorado.org for more information.
Program Chair:
-Robin Deterding, MD
Children's Hospital Colorado
Program Planning Committee:
-Alicia Casey, MD
Boston Children's Hospital
-Elizabeth Fiorino, MD
Northwell Health
-Jen Wambach, MS, MD
Washington University Physicians
-Lisa Young, MD
CHOP Research Institute
Program Faculty:
-Steve Abman, MD
Children's Hospital Colorado
-Kostas Alysandratos, MD
Boston University Medical Campus
-Emily DeBoer, MD
Children's Hospital Colorado
-Gail Deutsch, MD
Seattle Children's Hospital
-Samuel Goldfarb MD
University of Minnesota Physicians
-James Hagood, MD
University of North Carolina School of Medicine
-John Kennedy, MD
Boston Children's Hospital
-Rebekah Nevel
University of Missouri School of Medicine
-Craig Platt, MD
Boston Children's Hospital
-Greg Redding, MD
Seattle Children's Hospital
-Grant Schulert, MD, PhD
Cincinnati Children's Hospital
-Timothy Vece, MD
University of North Carolina, Children's Research Institute
-Jason Weinman, MD
Children's Hospital Colorado
-Jeff Whitsett, MD
Cincinnati Children's Hospital
Medical
Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Children’s Hospital Colorado designates this Live activity for a maximum of 8.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Attendance
A certificate of attendance will be provided upon completion of this course.
Available Credit
- 8.75 AMA PRA Category 1 Credit™
- 8.75 Attendance